Retatrutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The most common research dosage for Retatrutide is 4-12 mg weekly (maintenance after titration), administered once weekly via subcutaneous injection. Typical cycles run 48+ weeks (continuous therapy in trials). With a half-life of approximately 4-5 days, timing matters for optimal results.
What Is Retatrutide and Why Does Dosing Matter?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. Getting the dosage right is critical — too little may produce no measurable effect, while excessive amounts increase risk without proportional benefit.
The standard research dosage for Retatrutide has been established through preclinical studies and community protocols. This guide covers the evidence-backed dosing range, timing, and cycle structure.
What Is the Recommended Retatrutide Dosage?
The most widely used Retatrutide dosage is 4-12 mg weekly (maintenance after titration), administered once weekly via subcutaneous injection.
Beginners should start at the lower end of this range and titrate upward only if needed. The half-life of Retatrutide is approximately 4-5 days, which directly determines how often you need to dose to maintain stable blood levels.
For Retatrutide specifically, the 48+ weeks (continuous therapy in trials) cycle length is standard. Longer isn't always better — Triple hormone receptor agonist compounds require cycling to maintain receptor sensitivity.
When Should You Dose Retatrutide?
With a half-life of approximately 4-5 days, timing your Retatrutide administration affects peak blood levels. Most protocols call for once weekly.
For peptides administered before bed (common with GH-related compounds), the goal is to amplify the natural nocturnal growth hormone pulse. For healing peptides, proximity to the injury site via local injection can improve outcomes.
Calculate Your Retatrutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Retatrutide.
Open Calculator →How Do You Reconstitute Retatrutide?
Retatrutide typically comes as a lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water — never saline or sterile water, as BAC water contains 0.9% benzyl alcohol that prevents bacterial growth and extends shelf life to 4-6 weeks.
Use our peptide dosing calculator to determine the exact amount of BAC water to add based on your vial size and desired dose per injection.
How Long Should a Retatrutide Cycle Last?
Standard Retatrutide cycles run 48+ weeks (continuous therapy in trials). This timeframe is based on the compound's mechanism and the time needed to observe measurable effects.
Phase 3 TRIUMPH-4 reported 71.2 lb average weight loss (December 2025). Diabetes trial (TRIUMPH-1) showed 16.8% weight loss. Seven Phase 3 trials with results expected by year-end 2026. Over 20 ongoing clinical trials.
What Side Effects Can Affect Dosing?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
If side effects emerge, the first step is typically reducing the dose rather than discontinuing entirely. Most Retatrutide-related side effects are dose-dependent.
How Does Retatrutide Dosing Change When Stacking?
Triple agonism provides inherent synergy — not typically stacked with other GLP-1 or GIP agonists.
When stacking, some researchers reduce individual peptide doses by 20-30% since synergistic effects mean full doses of each aren't always necessary.
What Is the Bottom Line on Retatrutide Dosing?
Start at 4, dose once weekly, and run cycles of 48+ weeks (continuous therapy in trials). Monitor your response and adjust within the established range.
Source matters — always use research-grade Retatrutide from vendors with third-party COA testing. Underdosed or contaminated products are the most common reason for poor results.
Related Reading
- Retatrutide Benefits
- Retatrutide Side Effects
- Retatrutide Stacking Guide
- Retatrutide Cycle Guide
- Retatrutide Research
- CJC-1295 Complete Guide
Research-Grade Sourcing
If you're going to research Retatrutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What is the recommended Retatrutide dosage?
Common dosages: 4-12 mg weekly (maintenance after titration) administered once weekly via subcutaneous injection. Cycle length: 48+ weeks (continuous therapy in trials). Half-life: approximately 4-5 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Is Retatrutide safe?
Retatrutide has shown a preliminary safety profile in research. Not FDA-approved as of March 2026. NDA filing expected late 2026-early 2027. All research should follow appropriate safety protocols.